Levine Zurit 4

What Happened
Levine Zurit, SVP Business Development at Compugen Ltd (CGEN), reported exercising stock options and an open-market sale on April 24, 2026. The filing shows an exercise/acquisition of 2,000 shares at $1.15/share (cost $2,300) and an open-market sale of 2,000 shares at $3.20/share (proceeds $6,400). The report also records a separate derivative disposition of 2,000 shares at $0. Sales were made under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-04-24; Form 4 filed 2026-04-27 (appears timely).
• Exercise/acquisition: 2,000 shares @ $1.15 = $2,300 (transaction code M).
• Open-market sale: 2,000 shares @ $3.20 = $6,400 (transaction code S); footnote indicates sale pursuant to a Rule 10b5-1 plan (F1).
• Derivative disposition: 2,000 shares @ $0 recorded as an exercise/conversion (transaction code M) (listed as "Derivative").
• Shares owned after transaction: not reported in the provided data.
• Vesting note (F2): the option vested 25% on 9/30/2024; the remainder vests in 12 equal quarterly installments, subject to continued service.

Context
Zurit exercised options (paid $1.15 per share) and sold the same number of shares in the open market the same day; proceeds exceeded the exercise cost (gross proceeds $6,400 vs. exercise cost $2,300). The sale was executed under a 10b5-1 plan, which is a pre-arranged trading program and is often used to avoid the appearance of trading on inside information. The separate derivative line at $0 is recorded on the Form 4 but the filing does not provide additional detail on the exact settlement mechanics. This activity appears routine and pre-planned rather than an ad-hoc market-timing decision.